WO2001054766A1 - Systemes et procedes permettant l"echange de liquide cephalo-rachidien - Google Patents

Systemes et procedes permettant l"echange de liquide cephalo-rachidien Download PDF

Info

Publication number
WO2001054766A1
WO2001054766A1 PCT/US2000/002275 US0002275W WO0154766A1 WO 2001054766 A1 WO2001054766 A1 WO 2001054766A1 US 0002275 W US0002275 W US 0002275W WO 0154766 A1 WO0154766 A1 WO 0154766A1
Authority
WO
WIPO (PCT)
Prior art keywords
csf
replacement fluid
catheter
endogenous
fluid
Prior art date
Application number
PCT/US2000/002275
Other languages
English (en)
Inventor
Marvin L. Sussman
Tom A. Saul
David L. Karshmer
Original Assignee
Eunoe, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eunoe, Inc. filed Critical Eunoe, Inc.
Priority to PCT/US2000/002275 priority Critical patent/WO2001054766A1/fr
Publication of WO2001054766A1 publication Critical patent/WO2001054766A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A61M27/006—Cerebrospinal drainage; Accessories therefor, e.g. valves

Definitions

  • the present invention relates generally to medical devices and methods. More particularly, the present invention relates to devices, systems, methods, and kits for exchanging endogenous cerebrospinal fluid (CSF) with a CSF replacement fluid.
  • CSF cerebrospinal fluid
  • the brain and spinal cord are bathed in cerebrospinal fluid (CSF) and encased within the cranium and vertebral column inside a thin membrane known as the meninges (Fig. IN).
  • the space within the meninges includes the subarachnoid space SNS, the ventricles (including the lateral ventricle LV, third ventricle 3V, and fourth ventricle 4V), the vertebral column, and the brain interstitial spaces, and is referred to herein as the "CSF space.”
  • the volume of the brain intracranial spaces is on average about 1700 ml in mature adults.
  • the volume of the brain is approximately 1400 ml, and the volume of the intracranial blood is approximately 150 ml.
  • the remaining 150 ml is filled with CSF (this volume may vary within 60 ml to 290 ml).
  • the CSF circulates within the CSF space.
  • CSF is formed principally by the choroid plexuses which secrete about 80% of the total volume of the CSF.
  • the sources of the remainder are the vasculature of the subependymal regions and the pia matter.
  • the total volume of the CSF is renewed several times per day, so that about 500 ml are produced every 24 hours (equivalent to about 20 ml/hr or 0.35 ml/min) in healthy adults.
  • the production rate varies in the old and the young.
  • the cerebrospinal fluid is absorbed through the arachnoid villi, located principally over the superior surfaces of the cerebral hemispheres. Some villi also exist at the base of the brain and along the roots of the spinal nerves.
  • the absorptive processes include bulk transport as well as diffusion across porous membranes. Substances present in the CSF can be cleared by such absorptive processes. Large molecules and cellular debris are also cleared by pinocytosis. The production and absorption of CSF are well described in the medical literature. See, e.g., Ndams et al. (1989) "Principles of Neurology,” pp. 501-502.
  • CSF may come to contain undesirable substances which can be harmful to a patient and/or foul implanted devices.
  • diseases may be associated with toxic substances which are present in the CSF, such as Alzheimer's disease, Down's Syndrome, hereditary cerebral hemorrhage with amyloidosis of the Dutch-Type (HCHWA-D), epilepsy, narcolepsy, Parkinson's disease, polyneuropathies, multiple sclerosis, amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, dystrophy myotonic, other myotonic syndromes, polymyositis, dermatomyositis, brain tumors, Guillain-Barre-Syndrome, and the like.
  • HHWA-D hereditary cerebral hemorrhage with amyloidosis of the Dutch-Type
  • ALS amyotrophic lateral sclerosis
  • myasthenia gravis myasthenia gravis
  • muscular dystrophy dyst
  • CSF may become contaminated with deleterious drugs, either because of a drug overdose or because of an accidental administration of a wrong drug.
  • tumor cells can be released into CSF naturally or as a result of surgery on brain tumors, and the like.
  • the seeding of tumor cells into CSF circulation can place the patient at significant risk of metastatic tumor growth.
  • CSF can be contaminated by blood and high protein levels which can cause failure of the arachnoid villi and development of hydrocephalus.
  • Such high blood and protein levels can also render the implantation of a ventricular shunt or a lumbar shunt problematic by occluding passages in the shunt intended to permit release of CSF to treat hydrocephalus and related conditions.
  • the amount by which the concentration of any contaminating substance may be lowered is limited by the relatively slow rate of CSF replacement. Therefore, the rate at which the concentration is lowered is relatively slow, often taking a number of days to reach a new equilibrium. Such a slow process would often be ineffective for treating acute conditions, such as drug overdose or toxicity, the release of rumor cells following surgery, and the clearing of blood, proteins and other contaminating materials from CSF.
  • acute conditions such as drug overdose or toxicity, the release of rumor cells following surgery, and the clearing of blood, proteins and other contaminating materials from CSF.
  • U.S. Patent No. 4,686,085 describes a method for treating ischemic stroke by infusing an oxygenated mock CSF to a patient's cerebrospinal space and withdrawing CSF from a different location in the cerebrospinal space.
  • U.S. Patent No. 5,683,357 shows bi-directional CSF flow through a shunt in a hydrocephalus patient.
  • U.S. Patent No. 5,772,625 shows a hydrocephalus shunt without bi-directional flow.
  • U.S. Patent Nos. 5,002,528 and 4,895,561 show dual lumen catheters for infusing and removing fluids from body cavities.
  • the present invention provides improved and alternative methods and apparatus for removing and/or delivering substances to a patient's cerebrospinal fluid (CSF).
  • CSF cerebrospinal fluid
  • the present invention provides for removing toxic and other contaminating substances from the CSF in a patient's CSF space.
  • the present invention provides for delivering therapeutic and ameliorative agents to the CSF space, such as drugs, particularly chemotherapeutic drugs; biologicals, such as monoclonal antibodies; anesthetics; and the like.
  • the delivery and removal of the drugs or other active substances can be controlled to both provide rapid peaks and rapid removals, often permitting the use of higher concentrations and/or larger volumes of such substances than could be achieved by direct injection without the ability to remove the substance later.
  • the methods and apparatus may be used for a variety of purposes including the treatment of diseases associated with the accumulation of toxic substances in the CSF, such as Alzheimer's disease, and the other diseases listed above.
  • the present invention will be useful for treating acute drug toxicity in the CSF space, typically resulting from overdose, accidental dosages, and the like, as well as removing residual amounts of drugs and anesthetics which have been properly administered to a patient but which are no longer necessary. The latter will be useful in reducing post-surgical and other recovery times.
  • the present invention will still further be useful for removing toxic, immunogenic, neoplastic, and other deleterious substances which may be released into CSF circulation following surgery.
  • the present invention may be used to remove tumor cells which may be released into CSF circulation following the surgical removal of a tumor from the brain or other location that can release cellular substances into the CSF.
  • the present invention may find use in removing blood, proteins, and other contaminating substances which may be present in CSF prior to the implantation of a CSF drainage shunt or other surgical procedure in the CSF space.
  • the present invention is particularly advantageous since it can effectively reduce the concentrations of any of these substances to an arbitrarily low level.
  • the lowering of the concentration can be achieved in a relatively short period, typically less than 24 hours, often less than one hour, preferably less than 30 minutes, and more preferably less than ten minutes.
  • methods according to the present invention for reducing the concentration of a toxic substance in a CSF space of a patient comprise identifying a patient having a condition related to the presence of a toxic substance in CSF and exchanging endogenous CSF for a substantially equal volume of a CSF replacement fluid. In this way, the concentration of the toxic substance is reduced.
  • the identifying step may comprise identifying a patient having any of the diseases listed above, identifying a patient that has suffered a drug overdose or adverse drug reaction, or identifying a patient subject to the release of toxic substances in the CSF as a result of surgery, e.g., the release of tumor cells as the result of removal of a tumor.
  • the methods will also find use in treating patients about to undergo a surgical procedure in the CSF space, typically implantation of a CSF drainage shunt of the treatment of hydrocephalus or any of the other CSF-related diseases listed above.
  • These methods will all comprise identifying a patient about to undergo such a surgical procedure and thereafter exchanging endogenous CSF for substantially equal volume of the CSF replacement fluid in order to reduce the concentration of such substances in the CSF.
  • the latter method will be employed to reduce the concentration of contaminating substances which can be toxic (as discussed above) and can also foul the CSF drainage shunt or interfere with other surgical procedures.
  • a method for exchanging endogenous CSF in a CSF space of a patient with a CSF replacement fluid comprises implanting a single catheter so that a distal end of the catheter lies within the CSF space and a proximal end of the catheter lies outside of the patient. CSF replacement fluid is then infused through a first port on the distal end of the catheter into the CSF space. Endogenous CSF is removed through a second port on the distal end of the catheter from the CSF space.
  • the ports are spaced-apart and optionally oriented in different directions to minimize removal of the freshly introduced CSF replacement fluid.
  • a method according to the present invention for exchanging endogenous CSF in a CSF space of a patient with a CSF replacement fluid comprises infusing the CSF replacement fluid by positive displacement into the CSF space.
  • the endogenous CSF is removed, also by positive displacement from the CSF space.
  • the replacement fluid may be infused simultaneously with the removal of the endogenous CSF.
  • the replacement fluid will be infused at a rate which is substantially equal to the rate at which the endogenous CSF is removed in order to avoid any build up or depletion of fluid volume in the CSF space.
  • Exemplary infusion rates for the CSF replacement fluid on the range from 0.1 ml min to 50 ml/min, preferably from 1 ml/min to 15 ml min, with the difference between infusion and removal rates never exceeding 10 ml min, preferably never exceeding 1 ml/min, and more preferably being substantially equal.
  • the CSF replacement fluid may be infused sequentially with removing the endogenous CSF.
  • the infusing and removing procedures will be performed alternatingly, but in some instances it may be possible that they will partially overlap.
  • the volume of CSF replacement fluid infused and the volume of endogenous CSF removed at each cycle will usually be equal, typically being in the range from 10 ml to 200 ml, usually from 25 ml to 100 ml.
  • the total volume of CSF replacement fluid infused and endogenous CSF removed will usually be in the range from 50 ml to 2000 ml, more usually from 50 ml to 500 ml, and preferably from 50 ml to 150 ml.
  • the total volume will usually be removed over a relatively short period of time, typically from ten minutes to 24 hours, usually from ten minutes to two hours.
  • the difference between removed and infused volumes may be summed (totalized) over time to assure that there is no significant accumulation or depletion of total CSF present in the CSF space. Additionally, it may be desirable to weigh or otherwise keep track of the CSF replacement fluid which has been introduced (e.g., by monitoring the reduction in weight of the CSF replacement fluid source) and the amount of endogenous CSF removed (by monitoring the amount of fluid accumulating in the waste receptacle) in order to further assure that the fluid balance is being maintained properly.
  • the CSF replacement fluid will be infused to a pre-selected infusion location within the patient's CSF space and the endogenous CSF will be removed from a pre-selected removal location in the patient's CSF space.
  • the CSF space has been defined above, and the infusion location and the removal location are preferably spaced- apart by distance of at least 0.5 cm, preferably at least 4 cm, in order to assure that the CSF replacement fluid being infused will not flow directly into the removal location so that it is removed before it has a chance to mix with and dilute the endogenous CSF.
  • endogenous CSF is meant to include both the native CSF which is produced and secreted by the patient into the CSF space as well as any portion of the CSF replacement fluid which becomes mixed with the native CSF. While it will be desirable to the extent possible to avoid mixing and removal of the CSF replacement fluid, it will be appreciated that some mixing is inevitable and that removal of the CSF replacement fluid together with the native CSF will occur, particularly during latter stages of the treatment protocol. The removal of the CSF replacement fluid can be minimized, however, by spacing the removal location as far as possible from the infusion location, as discussed below.
  • the infusion and removal can be performed through a single lumen of a single catheter so that the infusion location and removal location are in fact at the same place.
  • this may be less efficient than other techniques described herein, it remains a viable approach for performing the methods of the present invention.
  • the infusion and removal locations may be virtually any portion of the CSF space, usually being within a ventricle, a cisterna magna, or a subarachnoid space.
  • the infusion and removal locations will usually be in the same region of the CSF space, typically being in a ventricle, most typically being in a lateral ventricle.
  • the infusion location and removal location may be present virtually anywhere in the CSF space, with exemplary infusion locations being in a lateral ventricle and a lumbar location (e.g., L3 to L5) and exemplary removal locations being in the cisterna magna, the lumbar region, and the like.
  • the CSF replacement fluid may be any sterile, physiologically compatible liquid which may be infused into the CSF space to temporarily replace the native or endogenous CSF as new endogenous CSF is produced and recirculated.
  • Suitable CSF replacement fluids include commercially available neurological irrigation fluids, such as Physiosol ® fluid (Abbott Laboratories), as described in the medical literature.
  • the present invention further provides systems for exchanging endogenous
  • a system comprises a source of CSF replacement fluid, a catheter having a proximal end, a distal end, and at least one lumen extending from near the distal end to near the proximal end, and first and second positive displacement liquid transfer devices.
  • the first positive displacement liquid transfer device such as a syringe, peristaltic pump, piston pump, or the like, is connected between a proximal end of the catheter lumen and the CSF replacement fluid source to deliver CSF replacement fluid through the lumen.
  • the second positive displacement liquid transfer device which can also be a syringe, a peristaltic pump, or a piston pump, is connected to the proximal end of the catheter lumen to remove endogenous CSF through that lumen.
  • This system is particularly suited for performing sequential infusion and removal operations where the first positive displacement liquid transfer device infuses the CSF replacement fluid through the single (common) lumen of the catheter while the second positive displacement liquid transfer device removes the endogenous CSF (typically, partially mixed with the CSF replacement fluid) through the same lumen.
  • systems according to the present invention comprise a source of CSF replacement fluid, a first catheter, and a second catheter, where both catheters have a proximal end, a distal end, and a least one lumen extending from near the distal end to near the proximal end.
  • the system further includes a first positive displacement liquid transfer device, which can be any of the devices listed above, connected between the proximal end of the first catheter lumen and the CSF replacement fluid source to deliver CSF replacement fluid through the lumen to the CSF space.
  • a second positive displacement liquid transfer device which can also be any of the devices disclosed above, is connected to the proximal end of the second catheter lumen to remove endogenous CSF through that lumen.
  • the second system is particularly suited for simultaneous infusion and removal of CSF from the CSF space where the distal ends of the first and second catheters are located at different positions within the CSF space. Since the first and second catheters are separate, they may be located at quite different locations, e.g., the first catheter may be in the lateral ventricle while the second catheter may be in a different ventricle, at the cisterna magna, or within the lumbar region of the subarachnoid space.
  • systems according to the present invention comprise a source of CSF replacement fluid and a single catheter having a proximal end, a distal end, and at least two isolated lumens extending from near the proximal end to near the distal end.
  • a first of the isolated lumens terminates at a first port near the distal end, and a second of the isolated lumen terminates at a second port near the distal end.
  • the first and second ports are spaced-apart by a distance of at least 0.5 cm, preferably at least 1 cm, and more preferably at least 4 cm.
  • the system may optionally comprise first and second positive displacement liquid transfer devices, or may comprise centrifugal pumps, or other non-positive displacement liquid transfer devices which may be controlled to provide desired infusion and/or removal volumes.
  • first and second positive displacement liquid transfer devices or may comprise centrifugal pumps, or other non-positive displacement liquid transfer devices which may be controlled to provide desired infusion and/or removal volumes.
  • These systems are particularly suitable for placement within a ventricle or other single location within the CSF space where the CSF replacement fluid may be infused at a location spaced-apart from the location from which it is withdrawn.
  • the first and second positive displacement liquid transfer devices will preferably be coordinated so that the volumes of CSF replacement fluid infused will be substantially equal to the volumes of endogenous CSF removed.
  • the coordination can be mechanical, e.g., the first and second positive displacement liquid transfer devices may be mechanically linked.
  • the amounts of CSF replacement fluid delivered and amounts of endogenous CSF removed may be monitored by conventional liquid flow monitoring devices. Based on the measured amounts or flow rates, the transfer devices can be controlled in order to equalize the volumes of fluid being delivered and removed. All the systems will preferably further comprise safety devices for stopping operation of the system in the event of over pressure, under pressure, or other dangerous operating conditions.
  • the typical over pressure value at which the system will be shut down is 5 cm H 2 0 over nominal measured ICP (intracranial pressure), while a typical under pressure value will be 5 cm H 2 0 under nominal measured ICP, preferably 5 cm H 0 under.
  • the present invention still further provides a cerebral fluid exchange catheter comprising a catheter body having a proximal end and a distal end.
  • An inflatable balloon is mounted at or near the distal end of the catheter body, and a lumen or other inflation tube or member is provided in or over the catheter body to permit selective inflation of the balloon when present in a ventricle or other body lumen.
  • At least one additional lumen or fluid delivery tube is also provided as part of the catheter to permit delivery of a fluid, typically a CSF replacement fluid, to a region outside of the balloon.
  • the catheter is typically used by introducing its distal end including the balloon into a ventricle or other body lumen.
  • the balloon is then inflated with a suitable inflation medium, typically physiological saline, mock CSF, radiopaque dye, or other incompressible fluid, and the CSF in the ventricle is displaced.
  • a suitable inflation medium typically physiological saline, mock CSF, radiopaque dye, or other incompressible fluid
  • an additional lumen in the catheter can be used for removing the displaced fluid, further optionally by the application of a negative pressure through said additional lumen.
  • the fluid can be simply displaced to other regions of the CSF space and/or withdrawn through a separate CSF removal catheter.
  • the balloon After the balloon has been fully inflated to displace a selected volume of CSF, typically in the range from 1 ml to 20 ml, preferably from 1 ml to 10 ml, the balloon will be deflated, and a volume of CSF replacement fluid introduced, typically simultaneously with the balloon deflation.
  • the balloons will be non- distensible so that they will inflate to predetermined volumes, not dependent on inflation pressure. Particular balloon styles may then be selected for an individual patient based on pre-operative imaging of the target ventricle.
  • the CSF replacement fluid will be introduced through a separate, isolated lumen within the catheter body, where the lumen has a port which lies adjacent to the balloon.
  • kits for performing any of the methods described above will include at least one implantable catheter having a proximal end, a distal end, and a lumen therethrough.
  • the kits will include instructions for use setting forth any of the methods described above.
  • kits may further comprise packaging for holding the catheter together with the instructions for use, wherein usually at least the catheter is maintained sterilely within the package.
  • kits may still further comprise a second implantable catheter having a proximal end, a distal end, and a lumen therethrough.
  • the kits may even further comprise a source of the CSF replacement fluid.
  • any of the systems described above may be provided in kit form where any or all of the kit components may be maintained sterilely within appropriate packages and wherein appropriate instructions for use are provided.
  • Fig. 1 illustrates the portions of the cranium and vertebral column which are encased within the meninges in which comprise the "CSF space" of the present invention. Specific regions within the CSF space are identified.
  • FIG. 2 is a schematic illustration of a first exemplary system according to the present invention for treating a patient.
  • Figs. 3 and 3A illustrate a catheter used in the system of Fig. 2.
  • Figs. 4A and 4B illustrate alternative fluid control units for the system of Fig. 2.
  • Fig. 5 illustrates a second exemplary system according to the present invention.
  • Fig. 6 illustrates a third exemplary system constructed in accordance with the principles of the present invention.
  • Figs. 7, 7A, and 7B illustrate a catheter which could be used in the methods of the present invention.
  • Figs. 8A and 8B illustrate flow control mechanisms that can be used in the systems of Figs. 5 and 6.
  • Fig. 9 illustrates a kit constructed in accordance with the principles of the present invention.
  • Figs. 10A - 10D illustrate use of the catheter of Figs. 7, 7A, and 7B in performing methods according to the present invention.
  • the system comprises a catheter 12 having a single lumen 14 and a plurality of infusion/aspiration ports 16 near its distal end.
  • the catheter has a connecting hub 18 at its proximal end, and the connecting hub 18 is connected to a flow control mechanism 20 which is described in more detail hereinafter.
  • Catheter 12 may optionally include a stylet 19 which can be placed in the lumen 14 of the catheter to stiffen the lumen and facilitate introduction to the CSF space of the patient.
  • the flow control mechanism 20 will receive a CSF replacement fluid from a source 22 and selectively deliver that replacement fluid to the catheter 12 so that it may be infused into a CSF space.
  • the flow control mechanism 20 will also receive endogenous CSF from the catheter 12 and direct the endogenous CSF to a waste disposal location 24.
  • the CSF replacement fluid source 22 may be a bag or other sterile receptacle for holding any of the liquids described earlier, while the waste receptacle 24 may be a bag, bottle, or other conventional medical liquid waste receptacle.
  • the flow control mechanism 20 may comprise any conventional liquid flow management apparatus capable of selectively delivering the CSF replacement fluid to the catheter and for selectively removing the endogenous CSF from the catheter. For example, as illustrated in Fig.
  • the mechanism 20 may comprise an infusion syringe 30 which contains the CSF replacement fluid and is able to deliver the fluid through a three-way connector or valve 32 into the proximal connecting hub 18.
  • the mechanism 20 will also include a removal syringe 40 which is able to apply a vacuum to the connecting hub 18 to withdraw endogenous CSF fluid from the catheter 12.
  • the CSF replacement fluid could be introduced as a bolus into the CSF space, allowed to mix for a short period of time, and thereafter withdrawn using the removal syringe 40. It will be appreciated that a significant portion of the CSF replacement fluid might be removed together with the endogenous CSF, thus reducing the effectiveness of the system.
  • FIG. 4A could be improved by connecting both the infusion syringe 30 and removal syringe 40 to a larger volume source of CSF replacement fluid and a larger receptacle, respectively. That way, the syringes could be used to alternatively pump and withdraw volumes of CSF from the CSF space in order to incrementally exchange the endogenous CSF for the CSF replacement fluid.
  • a pressure gauge 34 could be placed on the common inlet/outlet line to permit monitoring of the infusion removal pressures.
  • FIG.4B an alternative mechanism for sequentially delivering CSF replacement fluid and withdrawing endogenous CSF is illustrated.
  • CSF source 22 and waste receptacle 24 are connected to an alternative flow control mechanism 20'.
  • a one-way valve 50 permits the CSF replacement fluid to be drawn into infusion syringe 52 when the actuator handle 54 is moved in a rightward direction.
  • a removal syringe 54 is drawing endogenous CSF from the catheter 12 through another one-way valve 58.
  • the replacement fluid can be delivered to the catheter 12 by reversing the direction of actuator 54 to move in a leftward direction. This motion expels the CSF replacement fluid from syringe 52 through one-way valve 60 into the catheter.
  • the endogenous CSF in syringe 56 will be directed to the waste receptacle 24 by one-way valves 58 and 62. In this way a series of sequential pulses or small volumes of the CSF may be delivered to the patient while equal volumes of the endogenous CSF are removed from the patient.
  • a second system 100 comprising a catheter 102 having spaced-apart ports 104 and 106 near its distal end and a proximal connector 108 at its proximal end is illustrated.
  • the system 100 further includes a CSF replacement fluid source 110 and an endogenous CSF waste receptacle 112.
  • the system 100 includes a flow control mechanism 114 for controlling the flow of the CSF replacement fluid from the source 110 to port 104 and further controlling the flow of endogenous CSF fluid from port 106 to the waste receptacle 112.
  • Catheter 102 will include at least two isolated lumens, one from each of the ports 104 and 106 to separate connections of the connector 108. Exemplary flow control mechanisms will be described below.
  • a third system 200 (Fig. 6) according to the present invention includes a first catheter 202 having a distal end 204 with at least one infusion port thereon and a proximal connector 206.
  • a second catheter 208 has a distal end 210 with at least one aspiration port and a proximal connector 212.
  • the proximal connector 206 of infusion catheter 202 and the proximal connector 212 of aspiration catheter 208 are both connected to flow control mechanism 220 which will be described in more detail below.
  • the flow control mechanism 220 receives a CSF replacement fluid from a CSF replacement fluid source 222 and directs endogenous CSF from aspiration catheter 208 to a waste receptacle 224.
  • an exemplary catheter 400 comprises a catheter body 402 having a distal end 404 and a proximal end 406.
  • a balloon 410 (or other inflatable displacement member) is positioned at or near the distal end 404 of the catheter body 402, and a hub 412 is secured to the proximal end 406 of the catheter body.
  • the catheter body 402 comprises three fluidly isolated lumens 420, 422, and 424 (as best seen in Figs. 10A and 10B).
  • Lumen 420 is connected to an inflation connector 430 in hub 412 and terminates in an inflation port 432 within the balloon 410.
  • the second lumen 422 is connected to an aspiration connector 434 which terminates at an aspiration port 436 located immediately distal of the balloon 410.
  • the third lumen 424 is connected to an infusion connector 438 on the hub 412 and terminates in an infusion port 440 at the distal tip of the catheter.
  • a suitable inflation medium such as saline or other incompressible fluid, may be introduced through the connector 430 and into the balloon 410.
  • the same port and lumen may also be used to deflate the balloon.
  • the aspiration connector 434 may be connected to a suitable vacuum or reduced pressure source in order to aspirate CSF or other fluid through the port 436 from the ventricle or other body structure.
  • the CSF or other replacement fluid may be introduced through the infusion connector 438 and into the ventricle through the infusion port 440.
  • Figs. 10A - 10D Use of the catheter 400 for performing CSF removal and replacement is illustrated in Figs. 10A - 10D.
  • the distal end of the catheter 400 including balloon 410 in its deflated configuration is introduced to a brain ventricle BV in a conventional manner, typically through a sheath S.
  • the balloon 410 may be inflated, as shown in Fig. 10B. Inflation of the balloon directly displaces CSF from the brain ventricle. While displacement may result in fluid transport to other portions of the CSF space, it will be preferred that the displaced CSF be collected through the aspiration port 436, as illustrated.
  • a slight negative pressure typically in the range from 1 cm H 2 0 to 10 cm H 2 0, may be applied to assist in CSF removal.
  • the balloon 410 may be formed from a distensible or non-distensible material, preferably being non-distensible having a fixed, inflated volume in the range from 0.1 ml to 10 ml.
  • the inflation pressures will usually be moderate as described below.
  • the balloon 410 will be deflated, permitting introduction of the CSF replacement fluid.
  • CSF replacement fluid will be introduced through the distal port 440, as illustrated in Fig 10D.
  • the catheter may be used for further introduction of CSF replacement fluid, optionally in combination with a separate removal catheter, as described elsewhere in this application.
  • the balloon may be repeatedly inflated and deflated in order to introduce the CSF replacement fluid over time. Such repeat procedures may be performed at selected intervals, which may range from hours to days.
  • FIGs. 8A and 8B alternative flow control mechanisms 114 and 220 (Figs. 5 and 6, respectively) will be illustrated. Both these flow control mechanisms will work either with a single catheter having dual ports or dual catheters having single (or multiple) ports. Both will also provide for simultaneous delivery of CSF replacement fluid in aspiration of endogenous CSF.
  • the simplest flow control mechanism is illustrated in Fig. 8A where CSF fluid source 400 may be suspended above a flow control mechanism 402 having a one-way valve 404 in line with the fluid outlet line 406. Fluid from the source 400 will flow through the line 406, through the one-way valve 404, and to the delivery catheter 102 or 202.
  • the fluid will thus infuse into the target region of the CSF space based on the gravity head, typically 1 cm H 2 0 to 10 cm H 2 0 above measured intracranial pressure.
  • Infusion of the CSF replacement fluid into the CSF space will displace fluid into the catheter 102 or 202 and back through a line 410, through a one-way valve 412, and into a waste receptacle 420.
  • the one-way valves 404 and 412 are provided to assure that material from the catheter does not flow retrograde into the CSF replacement fluid source 400 and that waste CSF from receptacle 420 does not flow retrograde back into the patient.
  • System of Fig. 8 A is advantageous in that it operates solely on hydrostatic pressures induced by gravity.
  • a flow control mechanism 500 may comprise a pair of fluid transfer devices, typically positive displacement fluid transfer devices 502 and 504.
  • the controller 506 will control operation of both the infusion transfer device 502 and aspiration transfer device 504, typically electric pumps, more typically electric positive displacement pumps, such as peristaltic pumps.
  • Flow of CSF replacement fluid from a fluid source 510 will pass through the transfer device 502 to an output line 512 which will then pass to the infusion lumen of catheter 102 or 202.
  • Endogenous CSF from the aspiration lumen of catheter 102 or 203 will pass inwardly through line 520 to the second liquid transfer device 504 to a waste receptacle 530.
  • Control of both the infusion flow rates and aspiration flow rates may be accomplished by controlling the pump speeds, particularly in the case of positive displacement pumps, or by measuring the flows using flow measurement elements 540 and 542 placed in line in the infusion line 512 and aspiration line 520, respectively.
  • the flow control may be controlled through the positive displacement transfer devices 502 and 504 and additionally monitored using appropriate measurement systems to provide a further measure of safety that the amounts of CSF replacement fluid being delivered are equal to the amounts of endogenous CSF being removed.
  • One additional system which is not illustrated would utilize a pair of synchronized syringes, one coupled to an infusion lumen and the other coupled to a removal lumen.
  • the syringes would by driven simultaneously, but out-of-phase, so that one syringe would deliver fluid while the other would withdraw fluid.
  • kits comprising one or more system components together with instructions for use setting forth any of the above methods.
  • a kit may comprise at least one implantable catheter 700, usually also comprising at least a second implantable catheter 702 combination with instructions for use (IFU).
  • the catheters 700 and 702 together with the instructions for use with typically be packaged in a conventional medical device package 704, such as a pouch, tube, tray, box, or the like.
  • the kits may further comprise other components of the systems described above, such as the flow control mechanisms, the CSF replacement fluid sources, and/or the endogenous CSF waste receptacles. These components are shown schematically as 710 in Fig. 9. While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.

Abstract

L"invention concerne des procédés et des systèmes permettant l"échange de liquide céphalo-rachidien endogène (CSF) par un liquide de remplacement CSF (Fig. 9). Les procédés selon l"invention consistent à identifier des patients présentant des substances nocives ou contaminées dans le CSF d"un espace CSF, à infuser un liquide de remplacement CSF et à éliminer un volume équivalent de CSF endogène. De tels procédés permettent de réduire les concentrations de substances nocives ou contaminées à un volume arbitrairement faible. Les systèmes comprennent un ou plusieurs cathéters implantés (400) conjointement avec des mécanismes de réglage du débit (402) en vue de délivrer le liquide de remplacement CSF à un patient et d"éliminer le CSF endogène (7A). Les systèmes peuvent présenter des cathéters simples à lumières uniques pour infusion et retrait séquentiels (12). En variante, ces systèmes peuvent utiliser au moins deux lumières dans un ou deux cathéters en vue d"effectuer simultanément l"infusion et le retrait de CSF.
PCT/US2000/002275 2000-01-27 2000-01-27 Systemes et procedes permettant l"echange de liquide cephalo-rachidien WO2001054766A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2000/002275 WO2001054766A1 (fr) 2000-01-27 2000-01-27 Systemes et procedes permettant l"echange de liquide cephalo-rachidien

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/002275 WO2001054766A1 (fr) 2000-01-27 2000-01-27 Systemes et procedes permettant l"echange de liquide cephalo-rachidien

Publications (1)

Publication Number Publication Date
WO2001054766A1 true WO2001054766A1 (fr) 2001-08-02

Family

ID=21741009

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/002275 WO2001054766A1 (fr) 2000-01-27 2000-01-27 Systemes et procedes permettant l"echange de liquide cephalo-rachidien

Country Status (1)

Country Link
WO (1) WO2001054766A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060465A3 (fr) * 2002-12-23 2005-02-24 Scimed Life Systems Inc Procedes et appareils permettant de naviguer dans l'espace sous-arachnoidien
US7011647B2 (en) 2001-07-13 2006-03-14 Scimed Life Systems, Inc. Introducer sheath
US7455666B2 (en) 2001-07-13 2008-11-25 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
WO2011114260A1 (fr) 2010-03-19 2011-09-22 Pfizer Inc. Système de purification de liquide céphalorachidien
US8435204B2 (en) 2006-10-09 2013-05-07 Neurofluidics, Inc. Cerebrospinal fluid purification system
WO2016059162A1 (fr) * 2014-10-15 2016-04-21 P&X Medical Bvba Applications thérapeutiques de liquide céphalorachidien artificiel et outils prévus à cet effet
US9597480B2 (en) 2009-10-07 2017-03-21 Endophys Holding, LLC Intraluminal devices and systems
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
US10850235B2 (en) 2006-10-09 2020-12-01 Minnetronix, Inc. Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
US10874798B2 (en) 2014-10-15 2020-12-29 P&X Medical Nv Therapeutic applications of artificial cerebrospinal fluid and tools provided therefor
US20210100990A1 (en) * 2017-04-26 2021-04-08 National Cancer Center Skull implant-type automatic fluid drain device
US20210213260A1 (en) * 2016-02-18 2021-07-15 The Johns Hopkins University Systems and methods for controlling a volume of fluid within a portion of a patient's body
US11147540B2 (en) 2015-07-01 2021-10-19 Minnetronix, Inc. Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
US11577060B2 (en) 2015-12-04 2023-02-14 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683357A (en) * 1995-12-01 1997-11-04 Magram; Gary External cerebrospinal fluid drain apparatus
US6042598A (en) * 1997-05-08 2000-03-28 Embol-X Inc. Method of protecting a patient from embolization during cardiac surgery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683357A (en) * 1995-12-01 1997-11-04 Magram; Gary External cerebrospinal fluid drain apparatus
US6042598A (en) * 1997-05-08 2000-03-28 Embol-X Inc. Method of protecting a patient from embolization during cardiac surgery

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10315013B2 (en) 2001-07-13 2019-06-11 Endophys Holdings, Llc Sheath with sensing capabilities
US7011647B2 (en) 2001-07-13 2006-03-14 Scimed Life Systems, Inc. Introducer sheath
US7150737B2 (en) 2001-07-13 2006-12-19 Sci/Med Life Systems, Inc. Methods and apparatuses for navigating the subarachnoid space
US7455666B2 (en) 2001-07-13 2008-11-25 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
US7787954B2 (en) 2001-07-13 2010-08-31 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subaracnhnoid space
US8131353B2 (en) 2001-07-13 2012-03-06 Board Of Regents, The University Of Texas System Methods and apparatuses for navigating the subarachnoid space
US10716921B2 (en) 2001-07-13 2020-07-21 Endophys Holdings, Llc Methods of using a dual-lumen sheath in intraluminal procedures
US8961452B2 (en) 2001-07-13 2015-02-24 Board Of Regents, The University Of Texas System Multi-sheath member apparatus
JP2006511292A (ja) * 2002-12-23 2006-04-06 ボストン サイエンティフィック リミテッド くも膜下腔を進行するための方法及び装置
EP2022530A3 (fr) * 2002-12-23 2009-05-13 Boston Scientific Limited Appareil de réalisation de procédures dans l'espace subarachnoïde
JP4653494B2 (ja) * 2002-12-23 2011-03-16 ボストン サイエンティフィック リミテッド くも膜下腔を進行するための装置
WO2004060465A3 (fr) * 2002-12-23 2005-02-24 Scimed Life Systems Inc Procedes et appareils permettant de naviguer dans l'espace sous-arachnoidien
US8435204B2 (en) 2006-10-09 2013-05-07 Neurofluidics, Inc. Cerebrospinal fluid purification system
US11065425B2 (en) 2006-10-09 2021-07-20 Neurofluidics, Inc. Cerebrospinal fluid purification system
US9895518B2 (en) 2006-10-09 2018-02-20 Neurofluidics, Inc. Cerebrospinal fluid purification system
US11529452B2 (en) 2006-10-09 2022-12-20 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
US10398884B2 (en) 2006-10-09 2019-09-03 Neurofluidics, Inc. Cerebrospinal fluid purification system
US20200046954A1 (en) 2006-10-09 2020-02-13 Neurofluidics, Inc. Cerebrospinal fluid purification system
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
EP3827841A1 (fr) 2006-10-09 2021-06-02 Neurofluidics, Inc. Système de purification de fluide cérébrospinal
US10850235B2 (en) 2006-10-09 2020-12-01 Minnetronix, Inc. Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
US9597480B2 (en) 2009-10-07 2017-03-21 Endophys Holding, LLC Intraluminal devices and systems
US9913959B2 (en) 2009-10-07 2018-03-13 Endophys Holdings, Llc Device configured for real-time pressure sensing
WO2011114260A1 (fr) 2010-03-19 2011-09-22 Pfizer Inc. Système de purification de liquide céphalorachidien
US10874798B2 (en) 2014-10-15 2020-12-29 P&X Medical Nv Therapeutic applications of artificial cerebrospinal fluid and tools provided therefor
CN106794139A (zh) * 2014-10-15 2017-05-31 Px医疗公司 人造脑脊液的治疗应用和为其提供的工具
WO2016059162A1 (fr) * 2014-10-15 2016-04-21 P&X Medical Bvba Applications thérapeutiques de liquide céphalorachidien artificiel et outils prévus à cet effet
US11541175B2 (en) 2014-10-15 2023-01-03 P&X Medical Nv Therapeutic applications of artificial cerebrospinal fluid and tools provided therefor
US11147540B2 (en) 2015-07-01 2021-10-19 Minnetronix, Inc. Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
US11577060B2 (en) 2015-12-04 2023-02-14 Minnetronix, Inc. Systems and methods for the conditioning of cerebrospinal fluid
US20210213260A1 (en) * 2016-02-18 2021-07-15 The Johns Hopkins University Systems and methods for controlling a volume of fluid within a portion of a patient's body
US20210100990A1 (en) * 2017-04-26 2021-04-08 National Cancer Center Skull implant-type automatic fluid drain device
US11786710B2 (en) * 2017-04-26 2023-10-17 National Cancer Center Skull implant-type automatic fluid drain device

Similar Documents

Publication Publication Date Title
JP2776526B2 (ja) 逆行潅流の改良
WO2001054766A1 (fr) Systemes et procedes permettant l"echange de liquide cephalo-rachidien
EP1009276B1 (fr) Systeme de therapie dirigee
EP3827841B1 (fr) Système de purification de fluide cérébrospinal
US20220142806A1 (en) Urine Collecting System Interventions For Improving Kidney Function
EP0691866B1 (fr) Catheter a ballonnet et dispositif de perfusion le comportant
JP3677045B2 (ja) タイダル振動パルス腹膜透析のための装置
US20020107504A1 (en) Apparatus for local drug delivery in limb
EP1444001B1 (fr) Ensemble catheter d'administration de medicament a ballonnet gonflable
US20080146990A1 (en) Stroke intervention apparatus and method
WO2001039819A2 (fr) Procede et dispositif permettant la recirculation en circuit ferme d'un liquide cephalo-rachidien de synthese
WO1997040879A1 (fr) Methode therapeutique pour le traitement de la maladie d'alzheimer
WO2004058337A1 (fr) Catheters a multiples parties de perfusion, systemes et methodes
JPS62217974A (ja) 人工腺
JP2006525827A (ja) 移植可能ポンプ
JP2021523808A (ja) バルーンカテーテル
WO2010041084A1 (fr) Dispositif médical
US20070055196A1 (en) Implantable shunt system and method
JP7213528B2 (ja) 加圧式医薬品注入器
AT514812B1 (de) Aortenkatheter und Wiederbelebungsset mit einem solchen Aortenkatheter
US20220134076A1 (en) Implantable medical device for delivery of pharmacological agents to the deep brain structures
Johnson Nursing care of patients with implanted pumps
RU2118179C1 (ru) Способ управления обработкой вне организма и обратного вливания в организм биологических жидкостей
Kelleher et al. Drug therapy by indwelling arterial catheter
US20120277657A1 (en) Bicorporal partially subcutaneous positive displacement pump

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase